Skip to main content
Moogene Medi Co., Ltd. logo

Moogene Medi Co., Ltd. — Investor Relations & Filings

Ticker · 322970 ISIN · KR7322970005 KO Manufacturing
Open in API
Filings indexed 183 across all filing types
Latest filing 2020-10-08 Regulatory Filings
Country KR South Korea
Listing KO 322970

About Moogene Medi Co., Ltd.

http://moogene.com/eng/

Moogene Medi Co., Ltd. is a biotechnology company specializing in nanomedicine and the development of advanced drug delivery systems. The company focuses on its proprietary Lipid Nanoparticle (LNP) carrier system and other nano-bio technologies to safely and effectively transport a range of therapeutic agents, including genes, chemicals, and proteins. Its primary mission is to create novel therapeutics for severe and incurable diseases. The development pipeline includes gene therapies for conditions such as cancer, metabolic diseases, and androgenic alopecia, utilizing technologies like CRISPR/Cas9 gene editing. Moogene Medi operates an aseptic, GMP-grade facility, providing end-to-end support from initial research to GMP-scale production for clinical studies.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the suspension of share registration (shareholder register closure) for the purpose of determining shareholders for an Extraordinary General Meeting. It does not contain the full report or proxy materials themselves, but rather serves as a formal regulatory notice of a corporate action. Given the nature of the announcement and the lack of a specific category for 'Shareholder Register Closure', it falls under the general regulatory filing category.
2020-10-08 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including special relationships, director changes, and stock option grants. Since it reports significant changes in shareholding thresholds and ownership structure, it falls under the 'Major Shareholding Notification' category.
2020-09-08 Korean
[기재정정]주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea for reporting significant changes in share ownership (often referred to as the 5% rule). The text explicitly mentions '정정신고' (Correction Report) and provides detailed tables regarding shareholding ratios, special relationships, and changes in ownership. This falls under the 'Major Shareholding Notification' category.
2020-09-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. This type of filing is a mandatory disclosure by company insiders (directors/executives) regarding their personal shareholdings and transactions. In the provided classification schema, this corresponds to 'Director's Dealing' (DIRS), which covers insider trades and ownership reports by company directors and executives.
2020-09-07 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '임시주주총회 결과' (Extraordinary General Meeting Results) and details the outcomes of specific agenda items (election of directors and stock option grants) voted upon during the meeting held on 2020-09-01. This falls under the category of official results from shareholder votes at a general meeting.
2020-09-01 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to specific directors and employees, including exercise prices, vesting periods, and valuation methods. This type of disclosure regarding capital structure changes and equity-based compensation for executives falls under the category of share issues or capital changes, which is best classified as SHA.
2020-09-01 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.